NEW YORK (GenomeWeb News) – Rosetta Genomics reported after the close of the market on Friday that its revenues for full-year 2012 nearly doubled year over year.

Rosetta also announced a deal with Cantor Fitzgerald to serve as its agent in the sale of up to $5.9 million of its stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.